Advertisement

Picture Berlin Partner Bionnale 2021 Digital Event 650x80px
Organisation › Details

UCB S.A. (Euronext: UCB)

UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9 000 people in over 40 countries, UCB produced revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB). *

 

Period Start 1928-01-01 established
  Group UCB (Group)
Products Industry pharmaceutical
  Industry 2 CNS drug
Person Person Tellier, Jean-Christophe (201403– CEO-elect joined UCB 2011 before Ipsen + Macrogenics + Novartis)
     
Region Region Brussels
  Country Belgium
  Street 60 Allée de la Recherche
  City 1070 Brussels
  Tel +32-2-559-9999
    Address record changed: 2020-12-02
     
Basic data Employees G: 5,001 to 10,000 (2017-12-31)
  Currency EUR
  Annual sales 4,632,000,000 (revenue, consolidated (2018) 2018-12-31)
  Profit 823,000,000 (2018-12-31)
  Cash 1,049,000,000 (2017-12-31)
     
    * Document for �About Section�: 
     
   
Record changed: 2021-04-04

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for UCB (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80




» top